Acadia is funding and executing the development however under the agreement with Acadia Neuren gets input through a joint steering committee. Acadia has clearly prioristised Retts.
I also believe, although could be wrong, Fragile X may come under a different division with the FDA (Neurology vs Psychiatry). This would require a different approach to any potential P3 trial. As i said though, i coudl be wrong on that.
Acadia is funding and executing the development however under...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.522B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $3.519M | 290.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 25 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.28 | 319 | 4 |
View Market Depth
| Last trade - 13.09pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |